Welcome to our dedicated page for Sangamo Therapeutics news (Ticker: SGMO), a resource for investors and traders seeking the latest updates and insights on Sangamo Therapeutics stock.
Sangamo Therapeutics Inc (NASDAQ: SGMO) is a clinical-stage biopharmaceutical leader pioneering genomic medicines through innovative gene editing and gene therapy approaches. This dedicated news hub provides investors and researchers with timely updates on the company's scientific advancements, regulatory milestones, and therapeutic developments.
Access authoritative updates including press releases on clinical trial progress, partnership announcements with biotech leaders, and research breakthroughs in neurology, hemophilia, and rare genetic disorders. Our curated collection ensures you stay informed about SGMO's pipeline developments, including zinc finger protein therapies and in vivo genome editing applications.
Key content categories feature earnings reports, FDA regulatory updates, scientific publication highlights, and strategic collaboration news. Bookmark this page for direct access to primary source materials from Sangamo Therapeutics, maintaining your awareness of critical developments in precision genomic medicine.
Sangamo Therapeutics (SGMO) has entered into a license agreement with Eli Lilly for its proprietary neurotropic AAV capsid, STAC-BBB, which demonstrates strong blood-brain barrier penetration capabilities. The agreement includes:
- An $18 million upfront license fee
- Potential earnings of up to $1.4 billion in additional fees and milestone payments across five possible disease targets
- Tiered royalties on potential net sales
Lilly receives worldwide exclusive rights to use STAC-BBB for one initial target, with the option to add four additional targets for treating central nervous system diseases. This marks Sangamo's third agreement since announcing STAC-BBB in March 2024. Sangamo will handle the technology transfer, while Lilly will be responsible for research, development, manufacturing, and commercialization of resulting gene therapy products.
Sangamo Therapeutics (NASDAQ: SGMO) reported key developments and financial results for Q4 and full year 2024. The company secured two significant neurology license agreements: a global epigenetic regulation and capsid delivery agreement with Genentech and a capsid license agreement with Astellas, raising over $100M in non-dilutive funding.
Key highlights include: FDA clearance for ST-503 IND for treating intractable pain, with patient enrollment expected mid-2025; successful nonclinical proof of concept in prion disease; and alignment with FDA on Accelerated Approval pathway for isaralgagene civaparvovec in Fabry disease.
Financial results show Q4 2024 net loss of $23.4M ($0.11/share) compared to $60.3M loss in Q4 2023. Full-year 2024 net loss was $97.9M versus $257.8M in 2023. Q4 revenues were $7.6M, up from $2.0M in Q4 2023. Cash position stood at $41.9M as of December 31, 2024.
Sangamo Therapeutics (SGMO) has scheduled its fourth quarter and full year 2024 financial results release for Monday, March 17, 2025, after market close. The company will host an earnings conference call at 4:30 p.m. Eastern on the same day.
Additionally, Sangamo announced its participation in the Barclays 27th Annual Global Healthcare Conference in Miami, Florida, from March 11-13, 2025. CEO Sandy Macrae will present on Wednesday, March 12 at 12:00 p.m. Eastern. Both the earnings call and conference presentation will be accessible via webcast, with replays available afterward.
Sangamo Therapeutics announced updated data from Phase 1/2 STAAR study of isaralgagene civaparvovec (ST-920) for Fabry disease. Key findings show sustained benefits with elevated α-Gal A activity maintained for nearly four years in the longest-treated patient. The study demonstrated positive mean eGFR slope in 23 patients with one-year follow-up, indicating improved kidney function.
All 18 patients initially on enzyme replacement therapy (ERT) have successfully discontinued and remain off treatment. The therapy showed a favorable safety profile with mostly grade 1-2 adverse events and no treatment discontinuations. Quality of life measures showed significant improvements, including physical and emotional aspects.
Following FDA alignment on Accelerated Approval Pathway, Sangamo expects to submit data in first half of 2025, with potential BLA submission in second half of 2025. The company is actively pursuing business development discussions for potential ST-920 collaboration.
Sangamo Therapeutics (SGMO) will regain full rights to its hemophilia A gene therapy program, giroctocogene fitelparvovec, following Pfizer's decision to terminate their collaboration agreement effective April 21, 2025. Despite the Phase 3 AFFINE trial meeting primary and secondary endpoints with positive results, Pfizer has chosen not to proceed with Biologics License Application (BLA) and Marketing Authorisation Application (MAA) submissions.
The therapy demonstrated potential as a treatment for adults with moderately severe to severe hemophilia A. Sangamo plans to explore all options to advance the program, including seeking a new collaboration partner. The company remains focused on its neurology genomic medicine pipeline and Fabry gene therapy program, with partnerships with Genentech and Astellas supporting these initiatives.
Sangamo Therapeutics (SGMO) and Astellas Pharma have entered into a license agreement for Sangamo's proprietary neurotropic AAV capsid, STAC-BBB, which has shown strong blood-brain barrier penetration capabilities in nonhuman primates. The agreement grants Astellas worldwide exclusive rights to use STAC-BBB for one target, with options for four additional neurological disease targets.
Sangamo will receive a $20 million upfront license fee and could earn up to $1.3 billion in additional target fees and milestone payments across all five potential targets, plus tiered mid-to-high single-digit royalties on potential net sales. Astellas will handle all research, development, manufacturing, and commercialization activities, while Sangamo will complete the technology transfer.
Sangamo Therapeutics (Nasdaq: SGMO) received FDA clearance for its IND application for ST-503, an epigenetic regulator targeting chronic neuropathic pain in idiopathic small fiber neuropathy (iSFN). The company plans to initiate a Phase 1/2 study in mid-2025 to evaluate this one-time intrathecal treatment. ST-503 uses AAV vector technology with zinc finger repressors to target the SCN9A gene, which controls Nav1.7 sodium channels important for pain signaling. The treatment addresses iSFN, affecting an estimated 43,000 U.S. patients, with broader peripheral neuropathies impacting nearly 40 million Americans. Preclinical research showed promising results in reducing pain hypersensitivity with no off-target effects.
Sangamo Therapeutics reported significant Q3 2024 developments, including FDA's agreement for Accelerated Approval pathway for its Fabry disease gene therapy, potentially advancing approval by three years. The company received $50 million in upfront fees from Genentech, with potential for $1.9 billion in additional milestone payments. Q3 financial results showed net income of $10.7 million ($0.04 per share), with revenues of $49.4 million. Cash position stands at $39.2 million, expected to fund operations into Q1 2025. Pfizer will present Phase 3 AFFINE trial data for Hemophilia A gene therapy at ASH, showing positive results in meeting primary endpoints.
Sangamo Therapeutics (Nasdaq: SGMO) has announced it will release its third quarter 2024 financial results after market close on Tuesday, November 12, 2024. The company will host a conference call at 4:30 p.m. Eastern on the same day to discuss financial results and provide business updates. Participants can register for the call through a provided link and are advised to join 10 minutes before the start. The webcast will be available on Sangamo's website in the Investors and Media section, with a replay accessible afterward.
Sangamo Therapeutics (SGMO) reported Q2 2024 results and recent business highlights:
Key developments:
- Announced global license agreement with Genentech for neurodegenerative disease therapies, potentially worth up to $1.9 billion plus royalties
- Reported positive Phase 3 results for Hemophilia A gene therapy developed with Pfizer
- Continued progress in Phase 1/2 Fabry disease gene therapy trial
- Advancing neurology-focused preclinical pipeline
Financial results:
- Q2 net loss: $36.1 million ($0.18 per share)
- Q2 revenue: $0.3 million
- Cash position: $27.8 million as of June 30, 2024
- Expects $50 million in near-term payments from Genentech deal
Sangamo believes its cash runway extends into Q1 2025 with the Genentech payments.
FAQ
What is the current stock price of Sangamo Therapeutics (SGMO)?
What is the market cap of Sangamo Therapeutics (SGMO)?
